Business Insider

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...
IEEE

Impedance-Synthesized In-Band RCS Reduction for Ultrawideband Phased Array Antennas via Field–Circuit–Structure Co-Design Approach

Abstract: Achieving in-band radar cross section (RCS) in ultrawideband (UWB) phased array antennas (PAAs) is fundamentally constrained by the intrinsic coupling between radiation and scattering. This ...